For decades, the search for an Alzheimer's treatment has focused on clearing the wreckage left behind in the brain; now, researchers are asking whether the damage might be prevented before it begins. This week, scientists presented early evidence that diranersen, a drug developed by Biogen and Ionis Pharmaceuticals, can slow cognitive decline by instructing the body to produce less tau—the protein whose toxic tangles are believed to accelerate the disease's most devastating phase. The findings, modest and preliminary, nonetheless signal a meaningful turn in the field: from cleaning up amyloid
Experimental tau-targeting drug shows promise in slowing early Alzheimer's
Alzheimer's affects over 7 million Americans and tens of millions worldwide, making new treatment options critical for patients experiencing cognitive decline and memory loss.
Lowering tau production lets the brain's cleanup mechanisms keep pace
Mark
Why does it matter that diranersen works differently from the drugs already approved?
Mimi
Because we've been attacking the same target—amyloid—for years, and it helps but not enough. If tau is a separate driver of the disease, then blocking it might work where amyloid drugs plateau, or the two together might work better than either alone.
Mark
The study missed its main goal but still got published as promising. How do you square that?
Mimi
The primary endpoint was about dose-response—showing that more drug equals more benefit. That didn't happen. But the cognitive benefit itself was real and measurable. Sometimes the drug works, just not in the way you predicted. That's still valuable information.
Mark
Why inject it into the spinal fluid instead of the bloodstream like the other drugs?
Mimi
The blood-brain barrier is a filter that keeps most molecules out of the brain. Spinal fluid bathes the brain directly. It's a straighter route, which matters when you're trying to reach a target inside the brain itself.
Mark
The side effects sound mild compared to what?
Mimi
Anti-amyloid drugs can cause brain inflammation in some patients—a serious concern. Diranersen caused injection site pain and temporary confusion, which resolved. No brain inflammation signals. That's a meaningful safety difference.
Mark
What does the tau vaccine do that diranersen doesn't?
Mimi
Diranersen reduces tau production. The vaccine trains your immune system to recognize and attack tau that's already there. Different mechanisms, potentially complementary. You might use both.
Mark
Seven million Americans with Alzheimer's—how many could actually benefit from these new drugs?
Mimi
That's the open question. These trials focus on early disease, before major symptoms. If they work there, you might prevent or delay decline in millions. But we don't know yet if they'll help people with advanced disease.
O Pulso
- Alzheimer's affects more than seven million Americans, and the two drugs currently available can only modestly slow its progression—leaving millions with few options as the disease advances.
- Diranersen works through an entirely different mechanism than existing treatments, targeting tau protein production via spinal injection rather than clearing amyloid through the bloodstream, raising hopes for a complementary approach.
- The trial produced a confounding result: the lowest dose outperformed higher ones, causing the study to miss its primary endpoint—yet cognitive benefits still appeared across five of six brain tests, keeping the drug's promise alive.
- Experts are cautiously optimistic but insistent that larger trials are needed before diranersen can be considered a proven therapy, with researchers describing the results as 'quite promising if it were to hold up.'
- A broader wave of tau-targeting strategies—including vaccines, combination therapies, and novel drug-delivery systems designed to cross the blood-brain barrier—is now advancing simultaneously, suggesting the field is entering a new and more complex phase of Alzheimer's research.
For decades, the search for an Alzheimer's treatment has focused on clearing the wreckage left behind in the brain; now, researchers are asking whether the damage might be prevented before it begins. This week, scientists presented early evidence that diranersen, a drug developed by Biogen and Ionis Pharmaceuticals, can slow cognitive decline by instructing the body to produce less tau—the protein whose toxic tangles are believed to accelerate the disease's most devastating phase. The findings, modest and preliminary, nonetheless signal a meaningful turn in the field: from cleaning up amyloid to quieting tau at its source, and perhaps, one day, combining both strategies to hold the disease at bay before symptoms ever arrive.
Researchers this week unveiled early findings on diranersen, an experimental Alzheimer's drug that works by reducing the brain's production of tau—the protein whose toxic tangles are believed to drive the disease's most destructive phase. Developed by Biogen and Ionis Pharmaceuticals, the drug operates through a mechanism entirely distinct from lecanemab and donanemab, the two treatments currently on the market, which target amyloid plaques rather than tau.
Scientists believe Alzheimer's unfolds in stages: amyloid accumulates silently for decades before symptoms appear, then triggers tau to misfold inside neurons, accelerating cognitive decline. Diranersen is an antisense oligonucleotide—a molecule that instructs the gene responsible for tau production to make less of it—delivered by injection into the spinal fluid every six months, offering a more direct route to the brain than existing intravenous therapies.
In a trial of roughly 400 people with mild cognitive impairment or early Alzheimer's, the drug outperformed placebo on five of six cognitive tests. At the lowest dose, cognitive decline slowed by 26 percent—comparable to results seen in earlier amyloid-targeting trials. Side effects were manageable, and crucially, there were no signs of brain inflammation, a known risk with anti-amyloid drugs. The trial did, however, miss its primary endpoint: researchers had expected higher doses to produce stronger benefits, but the lowest dose proved most effective, upending the planned dose-response analysis.
Experts presented the results at the Alzheimer's Association International Conference in London with measured optimism. Jessica Langbaum of the Banner Alzheimer's Institute called the findings promising if they hold up in larger studies, while Dr. Reisa Sperling of Mass General Brigham suggested the work could reinvigorate investment across the broader tau research landscape.
Diranersen is one of several tau-targeting approaches now in motion. The University of California, San Francisco, recently launched a federally funded platform to test multiple anti-tau therapies—including a vaccine called AADvac1—both alone and in combination with existing amyloid drugs. Other researchers are exploring whether a cholesterol-lowering drug might also reduce Alzheimer's protein buildup in people carrying the APOE4 gene, while companies like Denali Therapeutics are engineering molecules that exploit the brain's iron transport system to deliver treatments more efficiently across the blood-brain barrier.
Together, these efforts represent a strategic shift in Alzheimer's research—from clearing protein buildup after the fact to preventing its formation in the first place. Whether that approach will prove superior, or whether the greatest gains will come from combining multiple mechanisms, remains an open question that larger trials now underway may begin to answer.
Researchers presented findings this week on an experimental drug that attacks Alzheimer's disease from a different angle than the treatments now available—by reducing production of tau, a protein that tangles inside neurons and destroys memory and thinking. The drug, called diranersen, made by Biogen in partnership with Ionis Pharmaceuticals, works through a mechanism entirely distinct from lecanemab and donanemab, the two Alzheimer's medications currently on the market, which instead target amyloid buildup in the brain.
Alzheimer's is thought to develop in stages. Amyloid protein begins accumulating in the brain roughly twenty years before symptoms appear, forming plaques. But amyloid alone doesn't cause the disease. Scientists believe that over time, amyloid triggers tau to misfold and tangle inside neurons, and that's when cognitive decline accelerates. The two existing drugs can modestly slow that decline by clearing amyloid. Diranersen takes a different path: it's an antisense oligonucleotide, a type of molecule that instructs the gene responsible for tau production to make less of the protein. By reducing tau at the source, the theory goes, the brain's natural cleanup mechanisms can keep pace with what remains, preventing the toxic tangles from accumulating.
In a trial of roughly 400 people with mild cognitive impairment or mild Alzheimer's disease, researchers found that diranersen recipients experienced slower cognitive decline than those given placebo. The results, presented at the Alzheimer's Association International Conference in London, showed that five of six different cognitive tests favored the drug group. In one test using the lowest dose—administered by injection into the fluid around the spinal cord every six months—the reduction in cognitive decline reached 26 percent, a magnitude comparable to what earlier trials showed for amyloid-targeting drugs. The spinal injection route offers a more direct path to the brain than the intravenous infusions or injections used for current Alzheimer's medications.
The trial did not go exactly as planned. Biogen had expected that higher doses would produce stronger benefits, but the opposite occurred: the lowest dose showed the most promise. This counterintuitive finding meant the study missed its primary endpoint, the planned demonstration of a dose-response relationship. Yet the cognitive benefits still emerged, and side effects were manageable—injection site pain and temporary confusion lasting about a week in some patients, but no signs of brain inflammation, a concern with anti-amyloid drugs. Experts cautioned that the results are preliminary. Jessica Langbaum of the Banner Alzheimer's Institute called the findings "quite promising if it were to hold up" in larger trials. Dr. Reisa Sperling of Mass General Brigham noted that while "it's early days," the work could "reinvigorate interest and investment in lots of tau mechanisms, and the field needs that."
Diranersen is one of several tau-targeting approaches now advancing. The University of California, San Francisco, last week launched the Alzheimer's Tau Platform, a National Institutes of Health-funded study designed to test multiple experimental anti-tau therapies, some alone and some combined with existing amyloid drugs. The first candidate is a vaccine called AADvac1, which trains the immune system to recognize and attack a specific problematic form of tau. The platform will expand to sites across the country and eventually include people who carry Alzheimer's-related protein buildup but have not yet developed symptoms.
Other novel approaches are also emerging. Researchers presented data on obicetrapib, an experimental cholesterol-lowering drug, which might also reduce buildup of Alzheimer's proteins in people carrying the APOE4 gene, a genetic risk factor for the disease. The gene affects both cholesterol metabolism and Alzheimer's risk, creating a potential dual benefit. NewAmsterdam Pharma plans to launch a trial soon. Meanwhile, companies like Denali Therapeutics are developing drugs that exploit the brain's natural iron transport system to deliver tau and amyloid-targeting molecules across the blood-brain barrier more efficiently and in higher concentrations.
Alzheimer's remains the leading cause of dementia, affecting more than seven million Americans and tens of millions of people worldwide. The disease's exact cause is still not fully understood, but the emerging consensus is that amyloid and tau work together to destroy the brain. The current arsenal of treatments can slow but not stop cognitive decline. Diranersen and the wave of tau-targeting therapies in development represent a significant shift in strategy—moving beyond clearing existing protein buildup to preventing its formation in the first place. Whether that approach will prove more effective, or whether the best results will come from combining multiple mechanisms, remains to be seen in the larger trials now underway.
Citações Notáveis
This is really quite promising if it were to hold up in larger testing— Jessica Langbaum, Banner Alzheimer's Institute
I think it will reinvigorate interest and investment in lots of tau mechanisms, and the field needs that— Dr. Reisa Sperling, Mass General Brigham
Quer a matéria completa?
Leia o original em Medical Xpress ↗
Health & Medicine